Harvard University-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Harvard University-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH4742D
  • |
  • Pages: 81
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Harvard University (Harvard) is an educational and research university that offers undergraduate and post graduate programs. The university offers courses such as accounting and management, anthropology, epidemiology, mathematics, music, pathology, psychology, sociology, visual and environmental studies, women's studies in religion, physics. It provides courses such as pediatric dentistry; landscape, architecture, and urban planning; biological chemistry and molecular pharmacology; comparative literature and microbiology and molecular genetics. Harvard offers libraries, museums, laboratories and research centers to support scholarly work. The university collaborates with other universities and research institutions for its research activities. It operates through various schools and colleges. Harvard is headquartered in Cambridge, Massachusetts, the US.

Harvard University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Harvard University, Medical Devices Deals, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deal Details

Partnerships

Frequency Therapeutics Enters into Agreement with Harvard University and US Army Institute of Surgical Research

Les Laboratoires Servier Enters into Agreement with Harvard University

Vir Biotechnology and Harvard University Enter into Research Agreement

Elysium Health Enters into Research Agreement with Harvard University

Thrive Bioscience and Harvard Stem Cell Institute Enter into Agreement

Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute

ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School

Medgenics Enters into Agreement with Harvard University

Ipsen Enters into Research Agreement with Harvard University

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute

Imcare Biotech Enters into Partnership with Harvard Medical School

Astellas Pharma Enters into Research Agreement with Harvard Medical School

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis

Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs

Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs

Pfizer Enters Into Co-Development Agreement With Harvard University

UCB Enters Into Co-Development Agreement With Harvard University

Evotec Enters Into Co-Development Agreement With Harvard University And BWH

Licensing Agreements

Mustang Bio Enters into Licensing Agreement with Harvard University

X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa

Nobilis Therapeutics Enters into Licensing Agreement with Harvard University

Merck Enters into Licensing Agreement with Harvard University

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology

Columbia Labs Enters into Licensing Agreement for IVR Technology

H&P Labs Enters into Licensing Agreement with Harvard University and Brigham and Women's Hospital

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology

Mesoblast Enters into Licensing Agreement with Harvard Medical School

Semma Therapeutics Enters into Licensing Agreement with Harvard University

Allied-Bristol Life Sciences Enters into Licensing Agreement with Harvard University

Macrolide Pharma Enters into Licensing Agreement with Harvard University Office of Technology Development

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology

GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School

TissueNetix Enters Into Licensing Agreement With Harvard University For Muscular Thin Film Technology

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates

SciFluor Life Sciences Extends Licensing Agreement With Harvard University For PET Imaging

Insero Health Enters Into Patent Licensing Agreement With Harvard University

Harvard University-Key Competitors

Harvard University-Key Employees

Harvard University-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Government and Public Interest

Mar 05, 2018: Personal cancer vaccines get their own boost

Dec 27, 2017: Technical University of Munich: Double strike against tuberculosis

Dec 20, 2017: CRISPR therapy preserves hearing in progressive deafness model

Nov 16, 2017: Study shows codeine prescribed to children despite FDA warning against it

Feb 10, 2017: U.S. Scientists Receive Inaugural $87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner

Product News

Nov 29, 2017: Innovative Microscope Poised to Propel Optogenetics Studies

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

Harvard University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

Harvard University, Medical Devices Deals, 2012 to YTD 2018

List of Tables

Harvard University, Pharmaceuticals & Healthcare, Key Facts

Harvard University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

Harvard University, Deals By Therapy Area, 2012 to YTD 2018

Harvard University, Medical Devices Deals, 2012 to YTD 2018

Harvard University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

Frequency Therapeutics Enters into Agreement with Harvard University and US Army Institute of Surgical Research

Les Laboratoires Servier Enters into Agreement with Harvard University

Vir Biotechnology and Harvard University Enter into Research Agreement

Elysium Health Enters into Research Agreement with Harvard University

Thrive Bioscience and Harvard Stem Cell Institute Enter into Agreement

Boehringer Ingelheim Enters into Research Agreement with Harvard Stem Cell Institute

ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School

Medgenics Enters into Agreement with Harvard University

Ipsen Enters into Research Agreement with Harvard University

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute

Imcare Biotech Enters into Partnership with Harvard Medical School

Astellas Pharma Enters into Research Agreement with Harvard Medical School

Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School

Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms

Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis

Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins

Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs

Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University

UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs

Pfizer Enters Into Co-Development Agreement With Harvard University

UCB Enters Into Co-Development Agreement With Harvard University

Evotec Enters Into Co-Development Agreement With Harvard University And BWH

Mustang Bio Enters into Licensing Agreement with Harvard University

X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa

Nobilis Therapeutics Enters into Licensing Agreement with Harvard University

Merck Enters into Licensing Agreement with Harvard University

Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology

Columbia Labs Enters into Licensing Agreement for IVR Technology

H&P Labs Enters into Licensing Agreement with Harvard University and Brigham and Women's Hospital

Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology

Mesoblast Enters into Licensing Agreement with Harvard Medical School

Semma Therapeutics Enters into Licensing Agreement with Harvard University

Allied-Bristol Life Sciences Enters into Licensing Agreement with Harvard University

Macrolide Pharma Enters into Licensing Agreement with Harvard University Office of Technology Development

Horizon Discovery Enters Into Licensing Agreement With Harvard University For Crispr Gene Editing Technology

GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School

TissueNetix Enters Into Licensing Agreement With Harvard University For Muscular Thin Film Technology

Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates

SciFluor Life Sciences Extends Licensing Agreement With Harvard University For PET Imaging

Insero Health Enters Into Patent Licensing Agreement With Harvard University

Harvard University, Key Competitors

Harvard University, Key Employees

Harvard University, Other Locations

Harvard University, Subsidiaries

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16648
Site License
USD 500 INR 33295
Corporate User License
USD 750 INR 49943

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com